Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Patiromer

    Client Email Product

    Patiromer

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Formulations

    GLOBAL SALES INFORMATION

    MARKET PLACE

    DIGITAL CONTENT

    PharmaCompass
    Related ProductsRelated Products
    API SUPPLIERS
    API Suppliers

    API Suppliers

    2
    US DMFs Filed

    US DMFs Filed

    0

    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    2
    API REF. PRICE (USD / KG)
    407

    API Market Place

    1
    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    4
    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    217.00

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS

    0

    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    7
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    Full View ScreenFull Screen View
    Vifor's hyperkalaemia drug Veltassa shows benefit in heart failure patients
    Vifor's hyperkalaemia drug Veltassa shows benefit in heart failure patients

    https://www.businesswire.com/news/home/20211220005646/en/Vifor-Pharma-reports-positive-outcome-of-the-phase-IIIb-DIAMOND-trial-of-Veltassa%C2%AE

    BUSINESSWIRE
    21 Dec 2021
    Share Share
    Vifor reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa
    Vifor reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa

    https://www.businesswire.com/news/home/20211220005646/en

    BUSINESSWIRE
    20 Dec 2021
    Share Share
    Vifor's Ferinject® granted new recommendations in ESC heart failure guidelines
    Vifor's Ferinject® granted new recommendations in ESC heart failure guidelines

    https://www.businesswire.com/news/home/20210830005519/en

    BUSINESSWIRE
    31 Aug 2021
    Share Share
    NICE reverses previous decision to recommend Vifor Pharma's Veltassa for NHS
    NICE reverses previous decision to recommend Vifor Pharma's Veltassa for NHS

    http://www.pharmafile.com/news/535799/nice-reverses-previous-decision-recommend-vifor-pharmas-veltassa-nhs-treatment-hyperkala

    PHARMAFILE
    16 Dec 2019
    Share Share
    Vifor Pharma’s Phase-II AMBER Study Meets Primary Endpoint
    Vifor Pharma’s Phase-II AMBER Study Meets Primary Endpoint

    https://www.businesswire.com/news/home/20190510005469/en/Vifor-Pharma%E2%80%99s-Phase-II-AMBER-Study-Meets-Primary/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==

    BUSINESSWIRE
    13 May 2019
    Share Share
    Vifor Pharma’s Phase-II AMBER Study Meets Primary Endpoint
    Vifor Pharma’s Phase-II AMBER Study Meets Primary Endpoint

    https://www.businesswire.com/news/home/20190510005469/en/Vifor-Pharma%E2%80%99s-Phase-II-AMBER-Study-Meets-Primary

    BUSINESSWIRE
    10 May 2019
    Share Share
    NICE turns down hyperkalaemia therapies
    NICE turns down hyperkalaemia therapies

    http://www.pharmatimes.com/news/nice_turns_down_hyperkalaemia_therapies_1257420

    Selina McKee PHARMA TIMES
    30 Oct 2018
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-05-06

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search